Monoclonal antibody · Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) · developed by Arcus Biosciences
Ralzapastotug is an IgG1 monoclonal antibody that binds TIGIT, an immune inhibitory receptor on tumor-infiltrating lymphocytes. By blocking TIGIT's interaction with CD112 and CD155, it allows these ligands to engage the costimulatory receptor CD226, promoting T-cell-mediated immune responses. It is being studied in multiple solid tumors and hematologic malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04772989 | Phase 1 | Advanced Solid Tumor | Completed | RCUS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorCervical CancerDiffuse Large B Cell Lymphoma (DLBCL)Esophageal CancerGastric CancerGastroesophageal Junction AdenocarcinomaLymphoma, Non-HodgkinMelanomaMultiple MyelomaNon Small Cell Lung Cancer (NSCLC)
Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.
See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RCUS catalysts and pipeline →